| INTRODUC TI ON
The current therapeutic approach to rheumatic diseases includes early and intensive treatment, aiming to reach persistent low disease activity and remission. Recently, new drugs increased the therapeutic options for patients, including both novel targeted therapies (biological disease modifying drugs) and biosimilars.
A biosimilar is a biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product.
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In recent years, with the aim to improve access to expensive biological agents and with the patent expiration of reference products, biosimilars have come to market.
Due to the complicated factors involved in manufacturing copies of biological therapeutic products, potential concerns on safety, efficacy and quality have been raised. In this context, the distinction between biosimilars and biomimics, that is versions of monoclonal antibodies or fusion proteins available in countries where regulation is less strict, is of great importance.
2 Unlike a biosimilar, these products don't have enough evidence to demonstrate biosimilarity and may therefore present clinically significant differences from the reference drug.
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With the introduction of biosimilars and biomimics in Latin America in the past years, regulatory authorities have been discussing and establishing the pathways to allow these drugs to receive market registration, whilst securing safety, quality and efficacy.
The regulatory scenario on biological medications in Latin
America is undergoing a full consolidation process as the region proceeds towards a stronger strictness on biosimilar registration. 
| REG UL ATORY PATHWAYS FOR B IOS IMIL AR S
The use of biological therapies in many Latin America countries consumes a substantial portion of the health care budget. Economic pressure to introduce biosimilar agents into market has forced regulatory agents to create different pathways to accelerate the process of licensing biosimilars.
Brazil regulations differ from other countries of Latin America. In 2010, ANVISA, the Brazilian Health Surveillance Agency introduced two pathways for approving comparable biological products, differing in the amount of data required for market approval: the comparative pathway and the individual development pathway.
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The comparative pathway is more rigorous, requires pharmacokinetic and pharmacodynamic studies and phase 3 trials, and allows extrapolations into other indications. This pathway is for licensing monoclonal antibodies and other complex molecules. Other countries like Bolivia and Ecuador are working on a regulatory draft.
| CON CLUS IONS
A substantial pipeline of biosimilars is in development with over 700 products reported to be in preclinical and clinical trials. Email: e.mysler@omiargentina.com.ar
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